[HTML][HTML] Epilepsy: Mitochondrial connections to the 'Sacred'disease
WH Moos, DV Faller, IP Glavas, I Kanara, K Kodukula… - Mitochondrion, 2023 - Elsevier
Over 65 million people suffer from recurrent, unprovoked seizures. The lack of validated
biomarkers specific for myriad forms of epilepsy makes diagnosis challenging. Diagnosis …
biomarkers specific for myriad forms of epilepsy makes diagnosis challenging. Diagnosis …
Therapeutic efficacy of voltage-gated sodium channel inhibitors in epilepsy
Epilepsy is a neurological disease characterized by excessive and abnormal hyper-
synchrony of electrical discharges of the brain and a predisposition to generate epileptic …
synchrony of electrical discharges of the brain and a predisposition to generate epileptic …
Real-life data comparing the efficacy of vigabatrin and oral steroids given sequentially or combined for infantile epileptic spasms syndrome
B Dozieres-Puyravel, H Nasser, FX Mauvais… - European Journal of …, 2024 - Elsevier
Abstract Aims The prognosis of Infantile epileptic spasm syndrome (IESS), relates to the
underlying etiology and delay in controlling epileptic spasms. Based on the spasm-free rate …
underlying etiology and delay in controlling epileptic spasms. Based on the spasm-free rate …
Safety of intravenous lacosamide in hospitalized children and neonates
SL Fong, L Utidjian, M Kaur, NS Abend… - …, 2023 - Wiley Online Library
Objective Seizures are common in critically ill children and neonates, and these patients
would benefit from intravenous (IV) antiseizure medications with few adverse effects. We …
would benefit from intravenous (IV) antiseizure medications with few adverse effects. We …
Pharmacogenetics and Oxcarbazepine in Children and Adolescents: Beyond HLA-B*15:02
SL Stancil, T Sandritter, JR Strawn - Journal of child and adolescent …, 2024 - liebertpub.com
Background: Oxcarbazepine is thought to be better-tolerated and less susceptible to drug–
drug interactions than its predecessor, carbamazepine. Genetic testing for HLA-B* 15: 02 is …
drug interactions than its predecessor, carbamazepine. Genetic testing for HLA-B* 15: 02 is …
What are the considerations when initiating treatment for epilepsy in children?
F Pisani, C Spagnoli - Expert Review of Neurotherapeutics, 2023 - Taylor & Francis
Introduction There is a very wide spectrum of epilepsies and developmental and epileptic
encephalopathies that affect children, from self-limited forms, not necessarily requiring …
encephalopathies that affect children, from self-limited forms, not necessarily requiring …
Benzodiazepines for pediatric epilepsies and their risks in a cohort within the French health care data
S Auvin, S Guillo, Y de Rycke, D Tran, F Tubach - Epilepsia, 2024 - Wiley Online Library
Objective The management of antiseizure treatment in patients with epilepsy relies on the
benefit–risk ratio. Data on antiseizure medication (ASM) use in children are limited. We …
benefit–risk ratio. Data on antiseizure medication (ASM) use in children are limited. We …
Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric patients with epilepsy: Model‐based dose optimization
W Wu, W Yang, X Xu, X Ge, J Lu… - Basic & Clinical …, 2024 - Wiley Online Library
The pharmacological activity of oxcarbazepine (OXC) is primarily exerted through its active
10‐monohydroxy metabolite (MHD). Nonetheless, there is limited pharmacokinetic …
10‐monohydroxy metabolite (MHD). Nonetheless, there is limited pharmacokinetic …
Brivaracetam as add-on therapy in children with developmental epileptic encephalopathies: A study of 42 patients
RH Caraballo, G Reyes, S Chacón, PS Fortini - Epilepsy & Behavior, 2024 - Elsevier
Objective Here we present a multicenter series of patients with developmental epileptic
encephalopathies (DEE) who were treated with brivaracetam (BRV) as add-on therapy …
encephalopathies (DEE) who were treated with brivaracetam (BRV) as add-on therapy …
[HTML][HTML] Initial combination versus early sequential standard therapies for Infantile Epileptic Spasms Syndrome—Feedback from stakeholders
PK Ramani, CB Abath, S Donatelli… - Epilepsia …, 2024 - ncbi.nlm.nih.gov
We read with great interest the report by Sourbron et al. 1 entitled “Medical Treatment in
Infants and Young Children with Epilepsy: Off‐label Use of Antiseizure Medications. Survey …
Infants and Young Children with Epilepsy: Off‐label Use of Antiseizure Medications. Survey …